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The pharmacokinetics of intravenously administered sulbactam were studied in 17 pedi-
atric patients two to 14 years of age. Single doses of 12.5 or 25 mg/kg were infused over
3 min, and in previously healthy children, mean peak plasma concentrations 5 min after
dosing were 71 and 163 ug/ml, respectively. Noncompartmental and compartmental cal-
culations resulted in similar pharmacokinetic parameters. Linear pharmacokinetics were
found in the concentration range studied. The mean terminal-phase half-life was 1.75hr,
the mean total plasma clearance was 180 ml/min per 1.73 m-, and the mean apparent
volume of distribution was 340 ml/kg. Approximately 70Ofo-80Ofo of an intravenous dose
was excreted unchanged in the urine. In children with cystic fibrosis, both total plasma
clearance and apparent volume of distribution weresignificantly increased. The data sup-
port the intravenous administration of 12.5-25 mg of sulbactam/kg every 6 to 8 hr for
assessing the adequacy of this drug as an adjunct to 13-lactam therapy for various bac-
terial infections in children.
An increasing number of gram-positive and gram-
negative organisms that cause infections in children
have become resistant to penicillin or cephalospo-
rin compounds through the production of 13-lacta-
mases, enzymes that destroy these antibiotics. One
way of restoring the susceptibility of resistant strains
of bacteria to these agents is by co-administering an
inhibitor of 13-lactamases. Sulbactam is a potent and
relatively stable 13-lactamase inhibitor that shows
promise as an adjunct to 13-lactam therapy.
The majority of the bacterial agents that cause re-
spiratory tract infections (e.g., pneumonia, bronchi-
tis, sinusitis, otitis), cellulitis, skeletal infections (e.g.
arthritis, osteomyelitis), urinary tract infections, and
meningitis in children are susceptible to sulbactam
plus ampicillin. This group of pathogens includes
the 13-lactamase-producing strains of Haemophi/us
influenzae, Staphylococcus aureus, and Escherichia
coli [1, 2].
In the present study we evaluated the pharmaco-
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kinetics of sulbactam in children. Such pharmacoki-
netic information should permit the formulation of
dosage recommendations for therapeutic trials of
this 13-lactamase inhibitor as an adjunct to a 13-lactarn
compound for pediatric infections.
Patients and Methods
Study patients. The pharmacokinetics of a sin-
gle iv dose of sulbactam was studied in 17 children
hospitalized at the Department of Pediatrics, Univer-
sity of Berne, for various bacterial infections (eight
for bronchopneumonia, five for meningitis, two for
lymphadenitis, one for arthritis, and one for epiglot-
titis). At the time ofthe study, both specific and non-
specific signs and symptoms of the actual infectious
disease had to have markedly improved. The pedi-
atric patients (PP) were divided into three groups
according to the dose of sulbactam (PP-l, 25 mg/kg;
and PP-2, 12.5 mg/kg) or underlying disease (PP-
CF, pediatric patients with cystic fibrosis treated for
bronchopulmonary exacerbations). Characteristics
of the groups of patients are listed in table 1. The
study participants included 11 boys and six girls.
They had no history of allergy to 13-lactam com-
pounds or of renal or hepatic diseases. The hydra-
tion and circulation status of each patient was judged
to be clinically normal. The study protocol con-
formed with the guidelines of the Institutional Com-
mittee on Human Investigations, Department of
Pediatrics, University of Berne; informed parental
consent was obtained for all study patients.
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Figure 1. Mean plasma concentration-time curves and mean cumulative percent recoveries of sulbactam in the urine
for the three pediatric patient (PP) groups studied. PP-I and PP-2 were previously healthy; PP-CF had cystic fibrosis.
The t Yz is terminal-phase half-life in hours (h). The bars indicate the SD values.
Hewlett-Packard 3380A, Palo Alto, Calif.) against
the concentration of sulbactam was constructed for
determining concentrations of sulbactam in patient
samples. Calibration curves werelinear over the con-
centration range 2-500 ug/ml, The lower detection
limit was 2 ug/ml, Coefficients of variation were
4.2070 for analyses performed on the same day
(within-day analysis), and 6.8% for day-to-day anal-
ysis (determined in spiked normal human plasma).
Estimationofpharmacokinetic parameters. Two
different methods of analysis (noncompartmental
and compartmental) were used for estimating the
clinically relevant parameters.
(1) Noncompartmental analysis: The area under
the plasma concentration-time curve (AVC) and the
area under the moment curve (AVMC) were calcu-
lated by fitting a spline function to the individual
data and integrating it. Extrapolation to infinity was
calculated according to Benet and Galeazzi [4]. The
curve used wasthe cubic natural spline.The terminal-
phase half-life was calculated by regression on those
plasma concentration points visually determined to
be in the log linear phase. Compartmental indepen-
dent plasma clearance (CI) was determined as origi-
nally described by Oost [5]: CI = dose/AVC. Vol-
ume of distribution at steady state (Vdss) is given:
Vdss = CI . MORT, where MORT is the mean dis-
position residence time, i.e., mean residence time af-
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ter an intravenous bolus. Thus, MORT =
AUMC/AUC and Vdss = dose· AUMC/AUC2 •
The total renal clearance (Cl-) was derived from
the 6-hr collectingintervalsby a semilogarithmic plot
of the excretion rate vs. the midpoint of the urine
collection period: Cl- = CI . Ae,,,,fdose, where Aeoo
is the amount of drug excreted unchanged in urine
to infinity.
(2) Compartmental analysis: For compartmental
analysis a two-compartment open-body model or a
one-compartment open-body model was necessary
for an adequate description of the individual plasma
concentration-time data after single iv doses of sul-
bactam. Nonlinear parameter estimation was per-
formed by the method of extended least squares [6]
with use of the computer program ELSFIT [7]. In
each case, a variance model with variances propor-
tional to some power at the predicted value at the
dependent variable was chosen [8].
Results
Plasma concentrations. Mean plasma concentra-
tions of sulbactam in the three patient groups are
listed in table 1. All ofthe predose samples were free
of sulbactam. Peak plasma concentrations, achieved
5 min after administration of a 25-mg/kg dose,
ranged from 113 to 286 ug/ml in previously healthy
children (PP-l) and from 68 to 103 ug/ml in chil-
dren with cystic fibrosis (PP-CF); after the admin-
istration of the 12.5-mg/kg doses, peak valuesranged
from 61 to 791lg/ml (PP-2). At 180min after dosing,
measured sulbactam concentrations were 4.7-14.3
ug/rnl in PP-l, 3.6-4.1 ug/rnl in PP-CF, and 3.8-6.2
ug/rnl in PP-2. After 360 min, all the plasma levels
either were not detectable (10 patients) or were be-
low the detection limit (2 ug/ml) of the HPLC
method used (sevenpatients). The mean plasma con-
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centration-time curves of the three patient groups
are included in figure 1. The individual data for
plasma concentration vs. time declined either mono-
or biexponentially and could be described by a one-
or a two-compartment open-body model.
The mean pharmacokinetic parameters, calculated
by noncompartmental and compartmental methods
are listed in table 2. Model-independent (noncom-
partmental) and model-dependent (compartmental)
valuesof terminal-phase half-life,total plasma clear-
ance, and volume of distribution werein good agree-
ment among the three patient groups. In previously
healthy children (PP-l and PP-2), both doses stud-
ied (25 and 12.5 mg/kg) produced similar phar-
macokinetic values. However, in the cystic fibrosis
group (PP-CF), the mean plasma clearance was 1'\.12.2
times and the mean volume of distribution was 1'\.11.6
times greater than the values for the other patient
groups. These increases led to significantly lower
peak plasma levels (table 1) and to slightly shorter
terminal half-lives (table 2).
Urine concentrations. Urine samples collected
before sulbactam administration contained no de-
tectable drug. The mean values (±SO) of the cumu-
lative percentage of the dose recovered in the urine
during the three 2-hr intervals from time 0 to 6 hr
after dosing are displayed in figure 1. Urine samples
were available from 12 of the 17 study patients. By
6 hr, 73070 (PP-l), 67% (PP-2), or 81% (PP-CF) of
the initial sulbactam dose was excreted unchanged
in the urine. The total amount of sulbactam excreted
unchanged in the urine to infinity and the fraction
of dose excretedunchanged could be calculated from
these data. Mean values (±SO) of this fraction were
0.81 (0.06) for PP-l, 0.73 (0.07) for PP-2, and 0.91
(0.06) for PP-CF. Therefore, renal clearances ac-
counted for 70%-90% of total plasma clearances.
Safety. Single doses of sulbactam administered
Table 2. Pharmacokinetic parameters of sulbactam calculated by noncompartmental and compartmental methods
for the three patient groups studied.
Noncompartmental model Compartmental model
CI CI
Patient Dose tv, (mllmin/ Vdss tv, (mllmin/ Vdss
group (mg/kg) (hr) 1.73 m
') (mllkg) (hr) 1.73 m') (mllkg)
PP-l 25 1.65 ± 0.98 187 ± 62 310 ± 154 1.74 ± 0.26 191 ± 69 312 ± 245
PP-2 12.5 1.77 ± 0.63 164 ± 29 385 ± 83 1.86 ± 0.21 172 ± 30 321 ± 132
PP-CF 25 1.42 ± 0.83 374 ± 35 701 ± 357 1.55 ± 0.13 445 ± 70 382 ± 120
NOTE. PP-l and PP-2 = previously healthy pediatric patients; PP-CF = pediatric patients with cystic fibrosis; tv, = terminal-
phase half-life; CI = plasma clearance; Vdss = volume of distribution at steady state.
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iv over 3 min were well tolerated. Although all of
the patients were receiving antibiotic drugs other
than the study drug, we perceived no local or sys-
temic reactions following the use of sulbactam that
we could ascribe to the drug mixtures. Obviously,
under the circumstances such data cannot be con-
sidered a definitive study of the toxicity of the
mixture.
Discussion
The pharmacokinetics of sulbactam administered iv
to children were studied. The pharmacokinetic values
for half-life, plasma clearance, and volume of dis-
tribution were similar in patients without cystic fibro-
sis given single doses of 12.5 or 25 mg of sul-
bactam/kg. It is therefore concluded that the
pharmacokinetics of sulbactam are linear in the con-
centration range studied.
The individual plasma concentration-time values
declined either mono- or biexponentially and, ac-
cordingly, could be described by a one- or a two-
compartment open-body model. The pharmacoki-
netic parameters calculated by the compartmental
method were in good agreement with the ones cal-
culated by the noncompartmental method. These
findings suggest that simple noncompartmental
pharmacokinetic analysis is adequate for iv ad-
ministered sulbactam in pediatric patients.
The ranges of plasma sulbactam concentrations
we observed after iv infusion of 12.5-mg/kg doses
are comparable to those reported for adult volun-
teers after 30-min iv infusion of 1,000 mg of sulbac-
tam [9]. The mean apparent volume of distribution
of 340 ml/kg estimated for previously healthy chil-
dren also compares favorably with the mean value
of 320 ml/kg for adult volunteers. However, the
mean total plasma clearance rate of 180 ml/min per
1.73 m" in children is substantially lower than the
mean value of "'240 ml/min per 1.73 m2 in adults
[9]. As a consequence, the mean terminal-phase half-
life of 1.75 hr in children is significantly longer than
the mean values of0.97 and 0.99 hr reported for adult
volunteers [9, 10].
The principal mode of elimination of sulbactam
is excretion of the structurally unchanged drug in
the urine. The renal clearance accounts for "'77"10
of the total plasma clearance of sulbactam in chil-
dren; a similar value has been reported for adults
[9, 10]. Thus, patients with renal dysfunction will
require adequate dosage adjustments.
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Pharmacokinetic studies of many 13-lactam and
aminoglycoside antibiotics have demonstrated al-
tered distribution and elimination of the drugs in
patients with cystic fibrosis as compared with the
normal population [11]. In the case of sulbactam,
both the apparent volume of distribution and the
total plasma clearance were significantly increased
in the patients with cystic fibrosis. Consequently, in
these patients the 25-mg/kg doses produced plasma
concentrations that were only approximately one-
half of those measured in previously healthy pedi-
atric patients; the mean terminal half-life was slightly
shorter (1.42 hr vs. 1.65 hr) in the cystic fibrosis pa-
tient group than in the previously healthy patient
group. Patients with cystic fibrosis will probably re-
quire increased dosages.
The pharmacokinetic data presented here and the
data on the 13-lactamase inhibitory activity of sul-
bactam in vitro [1, 2] indicate that a dosage of 12.5-
25 mg/kg given iv over 3 min every 6-8 hr should
be adequate for the study of sulbactam as an ad-
junct to iv 13-lactamtherapy for various bacterial in-
fections in children. At present, ampicillin appears
to be the most attractive parenteral partner for sul-
bactam in pediatric patients. The recommended dos-
age for ampicillin is twice the sulbactam dosage.
Studies of the co-administration of these compounds
in adults have repeatedly shown that the two are com-
patible and synchronous in their pharmacokinetics
[9, 10].
By analogy with single-drug therapy with ampicil-
lin, the dosage suggested above will probably have
to be increased two- to fourfold for treatment of in-
vasive infections. It must, however, be emphasized
that these dosage recommendations are preliminary
and are only intended for well-controlled clinical
evaluations.
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